Keywords
PharmacokineticsPharmacodynamicsTolerabilityMedicineDosingPharmacologyPartial thromboplastin timePlaceboOral administrationAdverse effectInternal medicineCoagulation
Affiliated Institutions
Related Publications
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects
Each single dose of rivaroxaban was well tolerated, with predictable pharmacokinetics and pharmacodynamics at doses up to 40 mg, and provided effective anticoagulation in health...
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patient...
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. ...
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
Oral antiplatelet drugs are a cornerstone of modern pharmacotherapy in cardiovascular atherothrombotic diseases. The efficacy of acetylsalicylic acid (ASA, aspirin) and clopidog...
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation....
Publication Info
- Year
- 2005
- Type
- article
- Volume
- 61
- Issue
- 12
- Pages
- 873-880
- Citations
- 648
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
648
OpenAlex
Cite This
Dagmar Kubitza,
Michael Becka,
Georg Wensing
et al.
(2005).
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects.
European Journal of Clinical Pharmacology
, 61
(12)
, 873-880.
https://doi.org/10.1007/s00228-005-0043-5
Identifiers
- DOI
- 10.1007/s00228-005-0043-5